NCT06128148View on ClinicalTrials.gov

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2027

Conditions
Protein Kinase InhibitorsOther Protocol Specified CriteriaLung NeoplasmsBrain Neoplasms
Interventions
DRUG

JYP0322 50 mg qd

JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 100 mg qd

JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 200 mg qd

JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 100 mg bid

JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 150 mg bid

JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 200 mg bid

JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.

DRUG

JYP0322 150mg tid

JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.

Trial Locations (1)

510060

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY